PF-06260414
Aliases: PF06260414
Last verified: 2026-09-23
The short version
A Pfizer SARM for cachexia/sarcopenia — Phase I completed, development discontinued. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Phase I completed; no further development. Status: discontinued. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A Pfizer SARM for cachexia/sarcopenia — Phase I completed, development discontinued.
Mechanism of action
Selective AR agonism.
not confirmed in humans
Dosing & routes
Official / clinical context
Development was abandoned; no active regulatory document exists. There are no official indications.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Phase I doses. No community experiences; Phase I only.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
No community experiences; Phase I only.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Phase I completed; no further development.
Preclinical evidence
Phase I completed; no further development.
Known risks
- Tolerated in Phase I.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.